|1.||Foster, Glen E: 3 articles (07/2015 - 03/2014)|
|2.||Lucas, Samuel J E: 3 articles (07/2015 - 03/2014)|
|3.||Stembridge, Mike: 3 articles (07/2015 - 03/2014)|
|4.||Ainslie, Philip N: 3 articles (07/2015 - 03/2014)|
|5.||Nkomo, Vuyisile T: 3 articles (11/2014 - 07/2008)|
|6.||Kataoka, Kazunori: 3 articles (02/2014 - 12/2008)|
|7.||Nishiyama, Nobuhiro: 3 articles (02/2014 - 12/2008)|
|8.||D'Andrea, Antonello: 3 articles (10/2013 - 01/2011)|
|9.||Bossone, Eduardo: 3 articles (10/2013 - 02/2013)|
|10.||López-Candales, Angel: 3 articles (04/2012 - 03/2005)|
03/15/2000 - "In contrast, all HAPE-S subjects revealed significantly greater increases (p = 0.002 vs. controls) in mean PASP both during hypoxia (from 28+/-4 to 57+/-10 mm Hg, deltaPASP 28.7+/-6 mm Hg) and during exercise (from 28+/-4 to 55+/-11 mm Hg, deltaPASP 27+/-8 mm Hg) than did control subjects. "
06/01/2012 - "This study investigated, for the first time, the effects of simulated high altitude, following acute hypobaric hypoxia (HH), on simultaneous assessment of large artery stiffness and endothelial function and its inter-relationship to left ventricular (LV) diastolic function, pulmonary artery systolic pressure (PASP), and estimated PA vascular resistance (PVR). "
03/15/2000 - "This prospective single-blinded study was performed to quantitate noninvasive pulmonary artery systolic pressure (PASP) responses to prolonged acute hypoxia and normoxic exercise. "
12/01/2015 - "However, the incidence of HAPE at 4559 m was much lower in altitude-naïve individuals with exaggerated pulmonary vasoconstriction (HPV) in normobaric hypoxia than in known HAPE-susceptibles, indicating that elevated PAsP alone is insufficient to induce HAPE. "
07/01/2015 - "The hypoxic ventilatory response (HVR) at sea level (SL) is moderately predictive of the change in pulmonary artery systolic pressure (PASP) to acute normobaric hypoxia. "
01/17/2012 - "The purpose of this study was to determine among community patients with heart failure (HF) whether pulmonary artery systolic pressure (PASP) assessed by Doppler echocardiography was associated with death and improved risk prediction over established factors, using the integrated discrimination improvement and net reclassification improvement. "
12/01/2012 - "In this study, we evaluated the mortality and hospitalization rates of subjects with raised PASP in a cohort of patients referred directly by their general practitioners for routine outpatient (open access) echocardiography for further analysis of suspected heart failure. "
07/01/2014 - "Although elevated pulmonary artery systolic pressure (PASP) is associated with heart failure (HF), whether PASP measurement can help predict future HF admissions is not known, especially in African Americans who are at increased risk for HF. "
11/01/2013 - "Echo-derived pulmonary arterial systolic pressure (PASP) and right ventricular (RV) tricuspid annular plane systolic excursion (TAPSE; from the end of diastole to end-systole) are of basic relevance in the clinical follow-up of heart failure (HF) patients, carrying two- to threefold increase in cardiac risk when increased and reduced, respectively. "
04/01/2013 - "To determine the prognostic relevance of the echocardiographic evaluation of pulmonary artery systolic pressure (PASP) and tricuspid annular plane systolic excursion (TAPSE) in patients with chronic heart failure (CHF). "
|3.||Dyspnea (Shortness of Breath)
04/01/2013 - "The efficacy of STS on PH was evaluated by measuring the pulmonary arterial systolic pressure (PASP), RV size by echocardiography, 6-minute walking distance (6MWD), Borg dyspnea score, and WHO functional class of PH. Patients aged from 17 to 46 (average 33±11) years old, pulmonary arterial systolic pressure (PASP) ranged from 60 to 140 mmHg, RV size ranged from 25 to 39 mm were included in study. "
06/12/2009 - "Mean age was 37 years and mean PASP was 40 mm Hg. The most frequent symptom was exertional dyspnea. "
07/01/2007 - "The change in 6MWD, echo-Doppler determined pulmonary artery systolic pressure (PASP), WHO Class and modified Borg Dyspnea Index (BDI) were assessed after each therapy. "
07/01/2003 - "During infusion, both mean transmitral gradient (6 +/- 3 versus 11 +/- 6 mmHg, p = 0.01) and pulmonary artery systolic pressure (PASP) (13 +/- 4 versus 21 +/- 3 mmHg, p < 0.001) were significantly increased in patients who developed dyspnea compared to others. "
10/03/2012 - "Accordingly, physicians commonly encounter patients with dyspnea, exercise intolerance, and/or right heart failure who have elevated pulmonary artery systolic pressure (PASP) on echocardiography. "
01/01/2015 - "Moreover, PEG-Phis/Pasp-DOX/CA4 resulted in enhanced therapeutic efficacy in drug-resistant tumors with reduced toxicity. "
01/01/2015 - "To enhance effective drug accumulation in drug-resistant tumors, a site-specific drug-releasing polypeptide system (PEG-Phis/Pasp-DOX/CA4) was exploited in response to tumor extracellular and intracellular pH. This system could firstly release the embedded tumor vascular inhibitor (CA4) to transiently 'normalize' vasculature and facilitate drug internalization to tumors efficiently, and then initiate the secondary pH-response to set the conjugated active anticancer drug (DOX) free in tumor cells. "
10/01/2015 - "The micelleplexes maintain structural stability at pH 7.4 ensuring long blood circulation and high tumor accumulation level, while they exhibit triggered release of secondary PAMAM-Pt(IV) dendrimer nanocarriers at tumoral acidity (≈pH 6.8) due to acid-labile charge-reversal properties of PAsp(EDA-DM) component under mildly acidic condition. "
04/03/2013 - "After reaching the tumor cells, the targeting property could be switched on by removing the PASP protection layer via hydrolyzation of PLGVR at the MMP-rich tumor cells, which enabled the easy uptake of drug-loaded nanoparticles by tumor cells and subsequent glutathione-induced drug release intracellularly. "
03/04/2013 - "Due to their strong red luminescence and good bioconjugatability, the antibody bioconjugated LaVO4:Eu(3+)-PASP NPs were successfully used as the biomarkers for cancer cell specific luminescence imaging. "
|5.||Liver Diseases (Liver Disease)
|2.||Biological Markers (Surrogate Marker)
|4.||Volatile Organic Compounds
|6.||Opioid Analgesics (Opioids)
|8.||tranilast (N 5')
|9.||Idiopathic pulmonary hypertension
|1.||Artificial Respiration (Mechanical Ventilation)
|2.||Length of Stay
|5.||Quantum Dots (Quantum Dot)